TOOBA PHARMACEUTICALS PRIVATE LIMITED

What TOOBA PHARMACEUTICALS PRIVATE LIMITED does

Tooba Pharmaceuticals Private Limited is a WHO-GMP certified manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, founded in 2007 by Dr. S M Jaweed Mukarram (formerly Senior Associate Director at Wockhardt) and headquartered in Chhatrapati Sambhajinagar (Aurangabad), Maharashtra, India. The company operates a single manufacturing facility in Paithan Industrial Area with capacity ranging from 1 kg to multi-tonne scales, and produces 13+ APIs including Trazodone Hydrochloride, Tamsulosin Hydrochloride, Mexiletine Hydrochloride, Glycopyrrolate, Baclofen, Carbimazole, Modafinil, Nitrofurantoin, Etoricoxib, Magnesium Aspartate, Primidone, and Cinacalcet Hydrochloride, in IP, USP, BP, and Ph.Eur grade specifications.

Its core technology centers on green chemistry principles, biocatalysis, metal catalysis, and the development of patentable, non-infringing synthetic routes. The company has filed a patent for the Glycopyrronium Bromide process (Application No. 202021022784), operates advanced reaction capabilities including hydrogenation, Grignard, photochemical, and high-temperature reactions up to 200°C, and maintains a Zero Liquid Discharge effluent treatment plant from inception. Capabilities include NDMA/nitrosamine risk assessments per ICH M7 and in-house preparation of impurities and working standards.

The business operates three revenue streams: (i) API bulk drug manufacturing (B2B sales of listed APIs and intermediates), (ii) CMO/CDMO services providing end-to-end contract manufacturing from lab to commercial scale, and (iii) CRO/R&D CRAMS services covering process optimization, analytical method development, and impurity profiling. The company employs 12 people, has no disclosed external funding, and reaches global pharmaceutical customers through direct enterprise field sales, supplemented by its website and LinkedIn presence. Revenue mechanics are contract-based and not publicly disclosed. Current regulatory footprint includes WHO-GMP, ISO 9001:2015, and COPP for 13 products, with EU GMP, US DMF, and UK DMF/EDQM filings actively in progress.

Name

TOOBA PHARMACEUTICALS PRIVATE LIMITED

Legal name

Tooba Pharmaceuticals Private Limited

Website

https://toobapharma.in

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Tooba Pharmaceuticals is a WHO-GMP certified Indian manufacturer of 13+ Active Pharmaceutical Ingredients and intermediates, offering CMO/CDMO and CRO/CRAMS services to global pharmaceutical companies from its single facility in Chhatrapati Sambhajinagar, Maharashtra.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical manufacturing
• API manufacturing
• Contract manufacturing
• Pharmaceutical intermediates
• Drug substances

Headquarters

HQ city

Chhatrapati Sambhajinagar

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. CMO/CDMO Services: Contract Development and Manufacturing Organization providing end-to-end solutions for APIs and intermediates, from laboratory scale to pilot and commercial manufacturing scales through WHO-GMP certified facility. Services include process development, technology transfer, validations, and regulatory filings.
2. CRO/CRAMS Services: Contract Research Organization and R&D CRAMS services offering process optimization, analytical and method development, impurity profiling & control, and troubleshooting for global pharmaceutical industry.
3. API Bulk Drugs Manufacturing: WHO-GMP Certified manufacturing and sale of Active Pharmaceutical Ingredients including Trazodone Hydrochloride, Tamsulosin Hydrochloride, Mexiletine Hydrochloride, Glycopyrrolate, Baclofen, Carbimazole, Modafinil, Nitrofurantoin, Etoricoxib, Magnesium Aspartate, Primidone, Cinacalcet Hydrochloride, and Glycopyrronium Bromide.
4. Pharmaceutical Intermediates: Manufacturing and supply of pharmaceutical intermediates used in API synthesis, including Trazodone intermediates, Tamsulosin intermediates, Mexiletine intermediates, and Glycopyrrolate intermediates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Tooba Pharmaceuticals Private Limited manufactures and supplies Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates from its WHO-GMP certified facility in Chhatrapati Sambhajinagar (Aurangabad), Maharashtra, India. In addition to commercial API supply across a portfolio of 12 molecules, the company provides CMO/CDMO contract manufacturing and CRO/CRAMS research services to pharmaceutical customers globally.

Product overview

Tooba Pharmaceuticals Private Limited is a WHO-GMP Certified manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates two primary service lines: CMO/CDMO services covering end-to-end contract manufacturing from laboratory to commercial scale, and CRO/R&D CRAMS services for process development and regulatory support. The product portfolio includes 12 marketed APIs including Trazodone Hydrochloride, Tamsulosin Hydrochloride, Mexiletine Hydrochloride, Glycopyrrolate, Baclofen, Carbimazole, Modafinil, Nitrofurantoin, Etoricoxib, Magnesium Aspartate, Primidone, and Cinacalcet Hydrochloride, along with approximately 10 pharmaceutical intermediates used in API synthesis.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 100% QMS documentation support
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Laurus Labs:
• Divis Laboratories: Large Indian API and intermediates manufacturer with global CDMO operations. Comparable as a contract manufacturer of generic APIs and intermediates with regulatory-grade facilities, though significantly larger and more diversified than Tooba.

Direct peers

• Neuland Laboratories: India-based API manufacturer and CDMO serving global pharma with small-molecule APIs, custom synthesis and CRAMS services. Closely comparable business model to Tooba — generic API portfolio plus CDMO/CRAMS — at a modestly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tooba-pharmaceuticals-private-limited

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TOOBA PHARMACEUTICALS PRIVATE LIMITED